1 Pharmacological activation of PKM2 slows lung tumor xenograft growth K. Mark Parnell 1 , Jason M. Foulks 1 , Rebecca N. Nix 1 , Adrianne Clifford 1 , Jeremy Bullough 1 , Bai Luo 1 , Anna Senina 1 , David Vollmer 1 , Jihua Liu 1 , Virgil McCarthy 1 , Yong Xu 1 , Michael Saunders 1 , Xiao-Hui Liu 1 , Scott Pearce 1 , Kevin Wright 1 , Marc O’Reilly 2 , Michael V. M c Cullar 3 , Koc-Kan Ho 1 and Steven B. Kanner 1 1 Astex Pharmaceuticals, Inc., Salt Lake City, UT 2 Astex Pharmaceuticals, Inc., Cambridge, UK 3 Astex Pharmaceuticals, Inc., Dublin, CA Running title: PKM2 activation inhibits lung tumor growth Key words: Lung cancer; screening strategies (assays and chemical libraries), experimental and molecular therapeutics; new targets; xenograft models; molecular pharmacology; novel antitumor agents; PKM2 Abbreviations: M2 isozyme of pyruvate kinase (PKM2); fructose-1,6-bisphosphate (FBP); phosphoenolpyruvate (PEP) Request for reprints: Steven Warner, 2401 South Foothill Drive, Salt Lake City, UT 84109, E-mail: swarner@toleropharma.com Conflict of interest: All authors are current or former employees of Astex Pharmaceuticals, Inc.